These results may explain cell-type-specific expression models or variability in the pathology and disease stages and clarify the molecular pathways in PSP, confirming the potential of LRRK2 as a therapeutic agent. The gene discussed is LRRK2; the disease is supranuclear palsy, progressive, 1.